vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and Kimco Realty (KIM). Click either name above to swap in a different company.
Kimco Realty is the larger business by last-quarter revenue ($558.0M vs $281.3M, roughly 2.0× Guardant Health, Inc.). Kimco Realty runs the higher net margin — 29.8% vs -45.7%, a 75.5% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 4.0%). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 5.6%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Kimco Realty Corporation, headquartered in Jericho, New York, is a real estate investment trust that invests in shopping centers.
GH vs KIM — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $558.0M |
| Net Profit | $-128.5M | $166.3M |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | 37.2% |
| Net Margin | -45.7% | 29.8% |
| Revenue YoY | 39.4% | 4.0% |
| Net Profit YoY | -15.8% | 23.7% |
| EPS (diluted) | $-1.01 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $558.0M | ||
| Q4 25 | $281.3M | $542.5M | ||
| Q3 25 | $265.2M | $535.9M | ||
| Q2 25 | $232.1M | $525.2M | ||
| Q1 25 | $203.5M | $536.6M | ||
| Q4 24 | $201.8M | $525.4M | ||
| Q3 24 | $191.5M | $507.6M | ||
| Q2 24 | $177.2M | $500.2M |
| Q1 26 | — | $166.3M | ||
| Q4 25 | $-128.5M | $151.2M | ||
| Q3 25 | $-92.7M | $137.8M | ||
| Q2 25 | $-99.9M | $163.0M | ||
| Q1 25 | $-95.2M | $132.8M | ||
| Q4 24 | $-111.0M | $166.0M | ||
| Q3 24 | $-107.8M | $136.0M | ||
| Q2 24 | $-102.6M | $119.7M |
| Q1 26 | — | — | ||
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — |
| Q1 26 | — | 37.2% | ||
| Q4 25 | -43.0% | 36.4% | ||
| Q3 25 | -37.3% | 34.9% | ||
| Q2 25 | -45.9% | 39.2% | ||
| Q1 25 | -54.6% | 33.6% | ||
| Q4 24 | -62.4% | 31.7% | ||
| Q3 24 | -61.3% | 33.7% | ||
| Q2 24 | -56.8% | 32.1% |
| Q1 26 | — | 29.8% | ||
| Q4 25 | -45.7% | 27.9% | ||
| Q3 25 | -35.0% | 25.7% | ||
| Q2 25 | -43.0% | 31.0% | ||
| Q1 25 | -46.8% | 24.8% | ||
| Q4 24 | -55.0% | 31.6% | ||
| Q3 24 | -56.3% | 26.8% | ||
| Q2 24 | -57.9% | 23.9% |
| Q1 26 | — | $0.46 | ||
| Q4 25 | $-1.01 | — | ||
| Q3 25 | $-0.74 | — | ||
| Q2 25 | $-0.80 | — | ||
| Q1 25 | $-0.77 | — | ||
| Q4 24 | $-0.90 | — | ||
| Q3 24 | $-0.88 | — | ||
| Q2 24 | $-0.84 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | — |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $10.4B |
| Total Assets | $2.0B | $19.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $378.2M | $211.6M | ||
| Q3 25 | $580.0M | $159.3M | ||
| Q2 25 | $629.1M | $226.6M | ||
| Q1 25 | $698.6M | $131.3M | ||
| Q4 24 | $525.5M | $688.6M | ||
| Q3 24 | $585.0M | $789.0M | ||
| Q2 24 | $933.7M | $126.4M |
| Q1 26 | — | — | ||
| Q4 25 | $1.5B | $7.7B | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | $8.0B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $10.4B | ||
| Q4 25 | $-99.3M | $10.4B | ||
| Q3 25 | $-354.5M | $10.5B | ||
| Q2 25 | $-305.5M | $10.5B | ||
| Q1 25 | $-250.8M | $10.6B | ||
| Q4 24 | $-139.6M | $10.7B | ||
| Q3 24 | $-60.1M | $10.5B | ||
| Q2 24 | $-1.6M | $10.6B |
| Q1 26 | — | $19.6B | ||
| Q4 25 | $2.0B | $19.7B | ||
| Q3 25 | $1.3B | $19.9B | ||
| Q2 25 | $1.3B | $19.8B | ||
| Q1 25 | $1.3B | $19.7B | ||
| Q4 24 | $1.5B | $20.3B | ||
| Q3 24 | $1.5B | $20.1B | ||
| Q2 24 | $1.6B | $19.5B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.74× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | — |
| Free Cash FlowOCF − Capex | $-54.2M | — |
| FCF MarginFCF / Revenue | -19.3% | — |
| Capex IntensityCapex / Revenue | 9.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-26.4M | $258.4M | ||
| Q3 25 | $-35.4M | $332.4M | ||
| Q2 25 | $-60.3M | $305.4M | ||
| Q1 25 | $-62.7M | $223.8M | ||
| Q4 24 | $-64.5M | $239.5M | ||
| Q3 24 | $-51.1M | $295.9M | ||
| Q2 24 | $-94.0M | $294.1M |
| Q1 26 | — | — | ||
| Q4 25 | $-54.2M | — | ||
| Q3 25 | $-45.8M | — | ||
| Q2 25 | $-65.9M | — | ||
| Q1 25 | $-67.1M | $205.4M | ||
| Q4 24 | $-83.4M | — | ||
| Q3 24 | $-55.3M | — | ||
| Q2 24 | $-99.1M | — |
| Q1 26 | — | — | ||
| Q4 25 | -19.3% | — | ||
| Q3 25 | -17.3% | — | ||
| Q2 25 | -28.4% | — | ||
| Q1 25 | -33.0% | 38.3% | ||
| Q4 24 | -41.3% | — | ||
| Q3 24 | -28.9% | — | ||
| Q2 24 | -55.9% | — |
| Q1 26 | — | — | ||
| Q4 25 | 9.9% | 0.0% | ||
| Q3 25 | 3.9% | 0.0% | ||
| Q2 25 | 2.4% | 0.0% | ||
| Q1 25 | 2.2% | 3.4% | ||
| Q4 24 | 9.4% | — | ||
| Q3 24 | 2.2% | — | ||
| Q2 24 | 2.9% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.71× | ||
| Q3 25 | — | 2.41× | ||
| Q2 25 | — | 1.87× | ||
| Q1 25 | — | 1.69× | ||
| Q4 24 | — | 1.44× | ||
| Q3 24 | — | 2.18× | ||
| Q2 24 | — | 2.46× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
KIM
| Revenues from rental properties, net | $552.8M | 99% |
| Management and other fee income | $5.2M | 1% |
